Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Ribociclib

1cf62fea-5134-50cf-a168-fafd4bbaf2ff · FDA Approved · targets CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_D1, CDK6_CYCLIN_D3, CDK6_CYCLIN_D2

Ribociclib

MeasuredReference

Ribociclib targets CDK4_CYCLIN_D3, CDK6_CYCLIN_D1, CDK4_CYCLIN_D1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

CDK4_CYCLIN_D3CDK6_CYCLIN_D1CDK4_CYCLIN_D1

Top hallmarks

  • tumor promoting inflammation880
  • evading apoptosis850
  • proliferation848

Top pathways disrupted

  • pi3k akt mtor signaling1.8k
  • apoptosis1.7k
  • apical junction1.6k

Resistance landscape — Ribociclib

MeasuredReference

No variant annotations found on Ribociclib's top targets.

No variant annotations on Ribociclib's top targets.
Open in new tab